Acetylator phenotype in relation to monoamine oxidase inhibitor antidepressant drug therapy.
The MAOI antidepressant drug phenelzine has a molecular structure closely related to drugs known to be acetylated, specifically isoniazid. Acetylator phenotype is genetically determined and shows wide variation between different ethnic groups. Acetylator phenotype could be a major factor as a determinant of response to phenelzine therapy and the findings from three studies are discussed. The implications for other (non-psychotropic) drug therapy are briefly referred to.
D000107:Acetylation; D003863:Depression / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010624:Phenelzine / Q000627:therapeutic use; D010641:Phenotype
D008996:Monoamine Oxidase Inhibitors; D010624:Phenelzine